Endogenous Opioid Systems and Symptom Change in Fibromyalgia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-30

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to study brain mechanisms associated with symptoms and severity of Fibromyalgia. This will be accomplished by relating results from PET scans to self-reported and objective measures of disease severity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Propranolol for Treating Fibromyalgia Pain

NCT03029845

Fibromyalgia Pain

TERMINATED PHASE1

Dynamic Contrast Enhanced (DCE)-MRI in Fibromyalgia

NCT01506817

Fibromyalgia

UNKNOWN

The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain

NCT02581332

Fibromyalgia

WITHDRAWN NA

Understanding and Restoring Dopaminergic Function in Fibromyalgia Patients

NCT04451564

Fibromyalgia

UNKNOWN NA

Mindfulness to Improve Functional Outcomes in Patients With Fibromyalgia or Central Sensitization

NCT03693274

Chronic Pain Fibromyalgia Central Sensitisation

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to examine µ-opioid receptor (µOR)-mediated neurotransmission in patients diagnosed with persistent pain, fibromyalgia (FM), and its relationship with pain and affect measures. µOR activation is expected to take place in the following brain regions: rostral and dorsal anterior cingulate (rACC, dACC), orbitofrontal cortex (OFC), thalamus (THA), nucleus accumbens (NAC), amygdala (AMY), periaqueductal gray (PAG). Greater regional activation is expected to be associated with improvements in clinical pain ratings and affective state.

The endogenous opioid system and µ-opioid receptors (µORs) play a central role in the regulation of pain, the pathophysiology of chronic pain syndromes, mood and emotion; this system is dysregulated in persistent pain syndromes. A substantial body of literature addressing these mechanisms has been developed in our laboratory, including recent data on the cognitive and molecular mechanisms associated with reductions in pain, as well as trait personality and genetic predictors of emotional effects in the context of pain.

Eighty individuals who have been diagnosed with FM and who fit the inclusion and exclusion criteria will be enrolled in this 14-week protocol. An initial visit for informed consent procedures and baseline characterization will then be scheduled, as well as the visits for positron emission tomography (PET) and magnetic resonance imaging (MRI) procedures. Subjects will return for testing after 6 and 14 weeks.

Volunteers will undergo imaging with structural and functional MRI and PET with \[11C\]carfentanil to determine baseline µOR non-displaceable binding potential (BPND) and changes in those BPND measures coinciding with symptom severity at the time of scanning.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fibromyalgia

No treatment

Intervention Type OTHER

Observation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No treatment

Observation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have met American College of Rheumatology (ACR) criteria for fibromyalgia for at least 1 year;
* Willing to limit introduction of new treatments during the study;
* Use of sleep aids no more than twice per week
* 18-55 years of age
* right handed
* capable of providing written informed consent

Exclusion Criteria

* concurrent untreated medical illnesses, autoimmune, or inflammatory disease;
* Routine daily use of narcotic analgesics or history of substance abuse;
* Concurrent participation in other therapeutic trials;
* Pregnancy/ nursing;
* Ongoing psychiatric illness;
* Contraindications to PET or MRI methods;
* Impairments that would prevent completion of the study protocol;
* Use of sleep aids at frequency of more that twice per week;
* Allergy to fentanyl

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No